← 返回

Thyroid dysfunction and cardiovascular disease.

Thyroid dysfunction and cardiovascular disease.

期刊: Eur Heart J 日期: 2026-01-01 PMID: 41996368 DOI: 10.1093/eurheartj/ehag248 浏览: 32
作者: Alwan Heba, Hysaj Ola, Gencer Baris, Duntas Leonidas, Rodondi Nicolas
Heba, A., Ola, H., Baris, G., Leonidas, D., & Nicolas, R. (2026). Thyroid dysfunction and cardiovascular disease.. Eur Heart J. https://doi.org/10.1093/eurheartj/ehag248
Heba A, Ola H, Baris G, Leonidas D, Nicolas R. Thyroid dysfunction and cardiovascular disease.. Eur Heart J. 2026; doi: 10.1093/eurheartj/ehag248
Heba A, Ola H, Baris G, et al. Thyroid dysfunction and cardiovascular disease.[J]. Eur Heart J. 2026. DOI: 10.1093/eurheartj/ehag248.
@article{heba2026,
  author = {Alwan Heba and Hysaj Ola and Gencer Baris and Duntas Leonidas and Rodondi Nicolas},
  title = {Thyroid dysfunction and cardiovascular disease.},
  journal = {Eur Heart J},
  year = {2026},
  doi = {10.1093/eurheartj/ehag248},
  note = {PMID: 41996368},
}
TY  - JOUR
AU  - Alwan Heba
AU  - Hysaj Ola
AU  - Gencer Baris
AU  - Duntas Leonidas
AU  - Rodondi Nicolas
TI  - Thyroid dysfunction and cardiovascular disease.
T2  - Eur Heart J
PY  - 2026
DO  - 10.1093/eurheartj/ehag248
AN  - PMID:41996368
ER  - 

摘要

Thyroid hormones play an important role in regulating the cardiovascular system. Thyroid dysfunction, which encompasses hypothyroidism and hyperthyroidism, is relatively common and has been linked to a range of cardiovascular manifestations, including dyslipidaemia, abnormal blood pressure regulation, endothelial dysfunction, impaired cardiac function, and arrhythmias. The effects of levothyroxine replacement therapy on cardiovascular endpoints in subclinical hypothyroidism remain uncertain. The largest randomized controlled trial (TRUST) to date was underpowered to assess cardiovascular outcomes, although the results demonstrated a pattern towards a beneficial effect of levothyroxine. The aim of this review was to provide a summary of current knowledge on the relationship between thyroid dysfunction and cardiovascular health, with a focus on molecular and pathophysiological mechanisms underlying thyroid dysfunction and cardiovascular disease. Evidence from recent omics and Mendelian randomization studies is discussed, alongside an overview of the epidemiology of thyroid diseases and the impact of levothyroxine treatment on cardiovascular outcomes in subclinical hypothyroidism.

AI 智能解读

相关文献

返回分类: 动脉粥样硬化 查看原文 (DOI)
已选择 0 篇文献